pipette
ESEspañol

Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease

Brage Brakedal, GEIR OLVE SKEIE, Carlotta Derad, Karl Bjørnar Alstadhaug, Ingunn Anundskås, Haakon Berven, Martin Biermann, Kari Anne Bjørnarå, Yamila N. Torres Cleuren, Solveig E J Dalbro, David Eidelberg, Kjartan Foldnes, Gabriela Fortes, Kristoffer Haugarvoll, Karen Herlofson, Eldbjørg Hustad, R.I. HogenEsch, Gard Aasmund Skulstad Johanson, Stein Harald Johnsen, Krisztina Kunszt, Simon Ulvenes Kverneng, Aliaksei Labusau, Ingeborg Haugesag Lie, Hallvard Lilleng, Katarina Lundervold, Christofer Lundqvist, Yilong Ma, Adrian McCann, Tormund Haugland Njølstad, Lasse Pihlstrøm, Frank Riemer, Anna Kaja Rognerud, Erika Veslemøy Sheard, Axel Meyer Simonsen, Eline Storm, Magnus Svensen, Lilah Toker, Jon‐Anders Tunold, Christian Dölle, Tim Friede, Charalampos Tzoulis

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Conclusions and Relevance Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes than placebo.

Appeared: Saturday, October 10. JAMA. Peer-reviewed journal.

DOI: 10.1001/jama.2026.18828